Redefining precision

A pathway to cancer-related immunoassays

Proclarix biomarkers were identified at the Swiss Federal Institute of Technology in Zurich (ETH Zurich) using a genetics-guided discovery approach focusing on the PI3K/PTEN cancer pathway. The latest proteomics technologies were used to analyze glycosylated proteins in prostate tissue and serum from wild-type mice and mice with prostate-specific deletion of the tumor suppressor PTEN. These findings were then translated into a blood-based test that measures cancer-related proteins in highly reproducible immunoassays.

Informed decisions with Proclarix

Proclarix (CE-IVD) is a breakthrough in identifying patients with elevated PSA who actually require more medical investigation. Proclarix is indicated in men with elevated total PSA (2.0 to 10.0 ng/ml) and a digital rectal examination finding consistent with elevated prostate volume (≥35 ml), but who are not suspected of having cancer. The Proclarix Risk Score identifies patients with a Gleason Score ≥7 in whom detecting high-grade prostate cancer with a prostate biopsy is probable.

A ready-to-use solution

Proclarix consists of two quantitative Enzyme-Linked Immunosorbent Assays (ELISA) that measure the concentration of thrombospondin 1 (THBS1) and cathepsin D (CTSD) respectively in human serum. A proprietary software integrates the values for THBS1 and CTSD, with age as well as total and free PSA to calculate the patient's Proclarix Risk Score.

Report shows the risk of high-grade prostate cancer

Proclarix integrates several proprietary biomarkers into a multidimensional signature of each patient's cancer-related proteins. The doctor receives a full report on all biomarker results and obtains a cumulative score giving a precise assessment of the prostate cancer risk.

Find further information about Proclarix and how to be tested for prostate cancer at your local laboratory.